Alcedis - a HUMA company

Did you miss our RWE #Webinar? No problem—you can watch the full recording at the link below! ⬇️ Gain insights from the #InspeCKD study with Dr. Nils Kost, Director Evidence at AstraZeneca. In this clip he explains why #RWE is crucial for any company to succeed in drug development. He later emphasizes: "Collaboration is essential. We need the entire healthcare system and all its stakeholders working together—our SHI system, physicians, and medical societies. Only through this united approach can we truly make a difference and improve the quality of care." A big thank you again to our speakers for their invaluable expertise and insightful presentations! Philipp Thiele Frederik M. Mader Dr. Hendrik Melior Follow this link to watch the full webinar: ➡️ https://lnkd.in/eCBapRci #DrugDevelopment #ClinicalTrials

Comprehensive clinical monitoring tailored to the specific needs of sponsors and their clinical trial projects. ⬇️ Benefit from our team of CRAs, experienced in a broad range of therapeutic areas and capable of every facet of monitoring, handling everything from creation of monitoring concepts to planning and execution of monitoring visits. Or use our stand-alone #software and guarantee GCP-compliant documentation, standardized site management, and efficient tooling. Click the link below to learn more about our monitoring services and software. ➡️ https://lnkd.in/eEHm46UR #ClinicalResearch #ClinicalTrials #ClinicalMonitoring #MonitoringSoftware

Did you miss our RWE #Webinar? No problem—you can watch the full recording at the link below! ⬇️ Gain insights from the #InspeCKD study with Dr. Nils Kost, Director Evidence at AstraZeneca. In this clip he explains why #RWE is crucial for any company to succeed in drug development. He later emphasizes: "Collaboration is essential. We need the entire healthcare system and all its stakeholders working together—our SHI system, physicians, and medical societies. Only through this united approach can we truly make a difference and improve the quality of care." A big thank you again to our speakers for their invaluable expertise and insightful presentations! Philipp Thiele Frederik M. Mader Dr. Hendrik Melior Follow this link to watch the full webinar: ➡️ https://lnkd.in/eCBapRci #DrugDevelopment #ClinicalTrials

Alcedis at the #𝗗𝗚𝗛𝗢 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in #Basel - a wonderful trip with many exciting lectures and insights from hematologic oncology. As one of the leading events for professionals in the German-speaking area, the conference regularly brings together experts from all around the globe to showcase innovative approaches in cancer and blood disease diagnosis and treatment.  Our highlights of the conference were the scientific symposia on anemia and antibody-based immunotherapies, as well as a very inspiring lecture on achievements with CAR-T cells. We have learned many things about #hematology and medical oncology in general, and listened to compelling presentations about AML therapy resistance and supportive therapies. Insightful discussions on the role of new approaches in advanced technologies and AI gave us the opportunity to improve our role as a #CRO in patient-centered therapies. Dr. Maja Treusch Katharina Fürst Dr. Janina Hoffmann #DGHO2024 #ClinicalTrials

Meet Alcedis at the 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in #Freiburg next week. This event presents an excellent opportunity to explore the utilization of Real-World Evidence data, particularly in relation to data capture, patient recruitment, retrospective analysis, and assessing trial feasibility for prospective post-market access studies. We consider this an area most suitable to be approached with #innovations and to apply new digital technologies. We will take a deep dive into the latest trends and challenges transforming evidence-based healthcare by engaging with various experts to discuss how we can actively influence the future of clinical research and improve patient care. We are especially looking forward to presentations from Ralf Patsch about the connection of EHR and RWE, as well as The Power of High-Quality Real-World-Data by Dr. Maike Sauer. Join Hanno Härtlein, Dr. Benedikt Linder and Dr. Hendrik Melior for compelling discussions on #RWE and market access strategies. See you there! MarketsandMarkets™ #marketsandmarkets #Conference #ClinicalTrials

Hello from #Heidelberg! We are at the 𝗕𝗶𝗼𝗥𝗡 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 today to explore the latest updates and advancements in biotechnology and new therapeutic approaches in personalized medicine, as well as to connect with #biotech experts from industry and academia. BioRN Life Science Cluster Rhine-Neckar Hanno Härtlein Dr. Marc Hetzel Dr. Benedikt Linder #BioRN #Biotechnology #ClinicalTrials

Just arrived in Berlin for the first #helmholtzhealthsummit. Perfect weather and a stunning Location. Looking forward to lots of interesting discussions and lectures. Alcedis - a HUMA company Helmholtz-Gemeinschaft

𝗪𝗲 𝘂𝗻𝗶𝘁𝗲 #𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 𝘁𝗼 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹𝗹𝘆 𝗲𝘅𝗲𝗰𝘂𝘁𝗲 𝘆𝗼𝘂𝗿 𝘀𝘁𝘂𝗱𝘆 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝘀. 🚀 As a full-service #CRO, we tailored our clinical expertise to support biotech companies in the efficient realization of clinical trials, translating the scientific foundation of their studies into a comprehensive development plan while managing the trial's duration and costs. With our experience in modern, patient-centered technologies, we open up new digital opportunities that can comprehensively demonstrate the innovative nature of new therapeutic approaches. Huma, a global healthcare AI leader that acquired Alcedis in 2023, invests in innovative companies to support and accelerate the development of new therapies and digital health solutions. Huma partners with more than 14 of the top 20 pharmaceutical companies across clinical trial phases to post-market launch and can act as a connector and enabler for the companies in which it invests, leveraging its deep C-level relationships. Click the link below to explore our Biotechnology services and contact our experts for further information. ➡️ https://lnkd.in/gQzixPWN #Biotechnology #Alcedis #ClinicalTrials

Witness #biotechnology and innovative Life-Science first-hand at 𝗕𝗶𝗼𝗥𝗡 𝗔𝗻𝗻𝘂𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟵, 𝟮𝟬𝟮𝟰 in #Heidelberg! We are excited to participate in this event, where leading minds from academia and industry will converge to share cutting-edge insights and bring together expertise in basic, applied and clinical research. The #conference offers a unique platform to gain insights into discoveries in epigenetics, RNA biology, and molecular glues. New capabilities for individual treatments and visions for personalized medicine are discussed, as well as collaborations that drive innovation and advancement in the biotech field. Presentations on next-generation radiotheranostics in modern cancer management or a Young Scientist Pitch Competition provide fascinating opportunities for this. Schedule a meeting with Hanno Härtlein, Dr. Marc Hetzel, and Dr. Benedikt Linder to observe Alcedis' expertise in executing study projects as we provide the integration of digital concepts and the necessary funding to efficiently performing biotech research. BioRN Life Science Cluster Rhine-Neckar #BioRN #ClinicalTrials

How do early detection and treatment of chronic diseases benefit from Real-World Evidence? Read our newest interview with Philipp Thiele, General Manager of CompuGroup Medical SE & Co. KGaA, exploring the advantages of #RWE in enhancing data capture for clinical research. He also addresses critical challenges that need to be solved to successfully integrate RWE into everyday clinical practice, offering insights into the future of data-driven healthcare. The #InspeCKD study by AstraZeneca, which was conducted in cooperation with Alcedis and @Intermedix, provides a real-life example for RWE, capturing anonymized electronic patient data to analyze the risk of CKD for patients with pre-existing conditions such as Diabetes mellitus, cardiovascular diseases, or hypertension. Read the full interview with Philipp Thiele at the link below. ➡️ https://lnkd.in/gCSXEcib #Blog #ClinicalTrials